Anacor Pharmaceuticals (ANAC) 16.58 $ANAC
Is Tenet Healthcare (THC) Poised to Beat Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 3:55PM CDT
Tenet Healthcare Corp. (THC) is set to report second-quarter 2014 earnings results on Aug 4, 2014.
Anacor Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Fri Aug 01, 3:00PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) will release its financial results for the second quarter ended June 30, 2014, on Thursday, August 7, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.
Anacor's Kerydin to Be Commercialized by Sandoz in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:05PM CDT
Anacor Pharmaceuticals, Inc. (ANAC) entered into an exclusive agreement with Sandoz, a Novartis company, for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals partners with Sandoz for commercialisation of KERYDIN in the US
M2 - Tue Jul 22, 8:35AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) revealed on Monday the launch of an agreement to distribute and commercialise its drug KERYDIN (tavaborole) topical solution, 5% in the US through Sandoz, a Novartis company.
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
3 Stocks Rising on Big Volume
at The Street - Tue Jul 22, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Monday’s Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech
Leo Sun, The Motley Fool - Motley Fool - Mon Jul 21, 8:06AM CDT
Let's take a look at three stocks -- Allergan , Anacor Pharmaceuticals , and Sinovac Biotech -- which could all loom large in health care headlines this Monday morning. Allergan tops earnings estimates for the second quarter Allergan...
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States
Business Wire - Mon Jul 21, 6:00AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's drug KERYDIN(TM) (tavaborole) topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, 2014, Anacor announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today.
This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 12, 2:57PM CDT
With the SPDR S&P Biotech Index up 28% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
3 Big-Volume Stocks in Breakout Territory
at The Street - Thu Jul 10, 8:18AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Anacor's Kerydin Gets FDA Nod for Onychomycosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 11:10AM CDT
Anacor Pharmaceuticals, Inc.'s (ANAC) Kerydin topical solution, 5% received approval in the U.S. for the topical treatment of onychomycosis of the toenails.
Why Anacor Pharmaceuticals Inc. Stock Briefly Dipped
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Anacor Pharmaceuticals , a...
FDA Approves Anacor Pharmaceuticals' KERYDIN(TM) (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails
Business Wire - Tue Jul 08, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN(TM) (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today.
Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
M2 - Mon Jun 30, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxlm9z/competitor) has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects. Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors. The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. Oral and Inhaled Non-Selective PDE-4 Inhibitors 2. Oral and Inhaled Seletive PDE-4 Inhibitors 3. Topical PDE-4 Inhibitors 4. Corporate PDE-4 Inhibitor R&D Pipelines Companies Mentioned - Alcon (a Novartis company) - Almirall - Anacor Pharmaceuticals - c-a-i-r Biosciences - Celgene - Chiesi Farmaceutici - Dainippon Sumitomo Pharma - Dart NeuroScience - Dermira - Eisai - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Kyorin Pharmaceutical - Maruho - MediciNova - Merck - Michael J. Fox Foundation - Orchid Chemicals & Pharmaceutical - Otsuka Pharmaceutical - Pharmaxis Sanofi - Takeda Pharmaceutical Co (Nycomed) - Tetra Discovery Partners - Verona Pharma For more information visit http://www.researchandmarkets.com/research/qxlm9z/competitor
The Race To The Market: Anacor and Valeant
Alexander Maxwell, The Motley Fool - Motley Fool - Wed Jun 18, 9:15AM CDT
For investors in Valeant Pharmaceuticals and Anacor Pharmaceuticals , it's an exciting time. Both of their Onychomycosis (a nail infection caused by fungus under the toenail or fingernail) drugs will hopefully hit the market within the next few...
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zp6w5m/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects Companies Mentioned: - Actavis plc - Eisai Co., Ltd. - Nihon Nohyaku Co., Ltd. - Helix BioMedix, Inc. - Kaken Pharmaceutical Co., Ltd. - Apricus Biosciences, Inc. - NovaBay Pharmaceuticals, Inc. - Nuvo Research Inc. - Mayne Pharma Group Limited - Evolva SA - Novabiotics Ltd - Anacor Pharmaceuticals, Inc. - NB Therapeutics, Inc. - NanoBio Corporation - Moberg Pharma AB - Viamet Pharmaceuticals, Inc. - Celtic Pharmaceutical Holdings L.P. - Meiji Seika Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/zp...chomycosis
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
FDA Oks Valeant toenail fungus treatment Jublia
By The Associated Press - AP - Mon Jun 09, 6:08AM CDT
The Food and Drug Administration has approved a toenail fungus treatment from Valeant Pharmaceuticals International Inc. that could reach $800 million in peak U.S. sales, according to the Canadian drugmaker.
Biotech Stocks Technical Report -- Research on Exact Sciences, Anacor Pharma, Cubist Pharma, and Agenus
PR Newswire - Mon Jun 09, 5:10AM CDT
On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.70, down 0.10%, while the index has advanced 3.94% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corp. (NASDAQ: EXAS), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agenus Inc. (NASDAQ: AGEN). Free technical research on EXAS, ANAC, CBST and AGEN can be downloaded upon signing up at:
Is Tenet Healthcare (THC) Poised to Beat Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 3:55PM CDT
Tenet Healthcare Corp. (THC) is set to report second-quarter 2014 earnings results on Aug 4, 2014.
Anacor Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Fri Aug 01, 3:00PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) will release its financial results for the second quarter ended June 30, 2014, on Thursday, August 7, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.
Anacor's Kerydin to Be Commercialized by Sandoz in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:05PM CDT
Anacor Pharmaceuticals, Inc. (ANAC) entered into an exclusive agreement with Sandoz, a Novartis company, for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals partners with Sandoz for commercialisation of KERYDIN in the US
M2 - Tue Jul 22, 8:35AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) revealed on Monday the launch of an agreement to distribute and commercialise its drug KERYDIN (tavaborole) topical solution, 5% in the US through Sandoz, a Novartis company.
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
3 Stocks Rising on Big Volume
at The Street - Tue Jul 22, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Monday’s Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech
Leo Sun, The Motley Fool - Motley Fool - Mon Jul 21, 8:06AM CDT
Let's take a look at three stocks -- Allergan , Anacor Pharmaceuticals , and Sinovac Biotech -- which could all loom large in health care headlines this Monday morning. Allergan tops earnings estimates for the second quarter Allergan...
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in the United States
Business Wire - Mon Jul 21, 6:00AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's drug KERYDIN(TM) (tavaborole) topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, 2014, Anacor announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today.
This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 12, 2:57PM CDT
With the SPDR S&P Biotech Index up 28% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
3 Big-Volume Stocks in Breakout Territory
at The Street - Thu Jul 10, 8:18AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Anacor's Kerydin Gets FDA Nod for Onychomycosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 11:10AM CDT
Anacor Pharmaceuticals, Inc.'s (ANAC) Kerydin topical solution, 5% received approval in the U.S. for the topical treatment of onychomycosis of the toenails.
Why Anacor Pharmaceuticals Inc. Stock Briefly Dipped
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Anacor Pharmaceuticals , a...
FDA Approves Anacor Pharmaceuticals' KERYDIN(TM) (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails
Business Wire - Tue Jul 08, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN(TM) (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today.
Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
M2 - Mon Jun 30, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxlm9z/competitor) has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects. Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors. The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. Oral and Inhaled Non-Selective PDE-4 Inhibitors 2. Oral and Inhaled Seletive PDE-4 Inhibitors 3. Topical PDE-4 Inhibitors 4. Corporate PDE-4 Inhibitor R&D Pipelines Companies Mentioned - Alcon (a Novartis company) - Almirall - Anacor Pharmaceuticals - c-a-i-r Biosciences - Celgene - Chiesi Farmaceutici - Dainippon Sumitomo Pharma - Dart NeuroScience - Dermira - Eisai - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Kyorin Pharmaceutical - Maruho - MediciNova - Merck - Michael J. Fox Foundation - Orchid Chemicals & Pharmaceutical - Otsuka Pharmaceutical - Pharmaxis Sanofi - Takeda Pharmaceutical Co (Nycomed) - Tetra Discovery Partners - Verona Pharma For more information visit http://www.researchandmarkets.com/research/qxlm9z/competitor
The Race To The Market: Anacor and Valeant
Alexander Maxwell, The Motley Fool - Motley Fool - Wed Jun 18, 9:15AM CDT
For investors in Valeant Pharmaceuticals and Anacor Pharmaceuticals , it's an exciting time. Both of their Onychomycosis (a nail infection caused by fungus under the toenail or fingernail) drugs will hopefully hit the market within the next few...
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zp6w5m/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects Companies Mentioned: - Actavis plc - Eisai Co., Ltd. - Nihon Nohyaku Co., Ltd. - Helix BioMedix, Inc. - Kaken Pharmaceutical Co., Ltd. - Apricus Biosciences, Inc. - NovaBay Pharmaceuticals, Inc. - Nuvo Research Inc. - Mayne Pharma Group Limited - Evolva SA - Novabiotics Ltd - Anacor Pharmaceuticals, Inc. - NB Therapeutics, Inc. - NanoBio Corporation - Moberg Pharma AB - Viamet Pharmaceuticals, Inc. - Celtic Pharmaceutical Holdings L.P. - Meiji Seika Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/zp...chomycosis
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
FDA Oks Valeant toenail fungus treatment Jublia
By The Associated Press - AP - Mon Jun 09, 6:08AM CDT
The Food and Drug Administration has approved a toenail fungus treatment from Valeant Pharmaceuticals International Inc. that could reach $800 million in peak U.S. sales, according to the Canadian drugmaker.
Biotech Stocks Technical Report -- Research on Exact Sciences, Anacor Pharma, Cubist Pharma, and Agenus
PR Newswire - Mon Jun 09, 5:10AM CDT
On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.70, down 0.10%, while the index has advanced 3.94% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corp. (NASDAQ: EXAS), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agenus Inc. (NASDAQ: AGEN). Free technical research on EXAS, ANAC, CBST and AGEN can be downloaded upon signing up at:
